en
Feedback
๐—”๐—ฅ๐—ข๐—ก ๐—ฆ๐—ง๐—จ๐——๐—ฌ

๐—”๐—ฅ๐—ข๐—ก ๐—ฆ๐—ง๐—จ๐——๐—ฌ

Open in Telegram

ุจุณู… ุงู„ู„ู‡ ุงู„ุฑุญู…ู† ุงู„ุฑุญูŠู… ุงู„ู„ู‡ู… ุตู„ ุนู„ู‰ ู…ุญู…ุฏ ูˆุขู„ ู…ุญู…ุฏ ู…ุญุชูˆู‰ ุงู„ู‚ู†ุงุฉ: ุดุฑูˆุญุงุช ุตูŠุฏู„ุฉ ุนุถูˆูŠุฉ ู…ุฑุญู„ุฉ ุซุงู†ูŠุฉ ูƒูˆุฑุณ ุซุงู†ูŠ ูุงุฑู…ุง ู…ุฑุญู„ุฉ ุซุงู„ุซุฉ ูƒูˆุฑุณ ุซุงู†ูŠ ูุงุฑู…ุง ู…ุฑุญู„ุฉ ุฑุงุจุนุฉ ูƒูˆุฑุณ ุงูˆู„ ูุงุฑู…ุง ู…ุฑุญู„ุฉ ุฑุงุจุนุฉ ูƒูˆุฑุณ ุซุงู†ูŠ ุนู„ุงุฌูŠุงุช ู…ุฑุญู„ุฉ ุฎุงู…ุณุฉ ู„ู„ุชูˆุงุตู„: @AronX2bot

Show more

๐Ÿ“ˆ Analytical overview of Telegram channel ๐—”๐—ฅ๐—ข๐—ก ๐—ฆ๐—ง๐—จ๐——๐—ฌ

Channel ๐—”๐—ฅ๐—ข๐—ก ๐—ฆ๐—ง๐—จ๐——๐—ฌ (@aronstudy) in the Arabic language segment is an active participant. Currently, the community unites 13 355 subscribers, ranking 1 923 in the Medicine category and 5 681 in the Saudi Arabia region.

๐Ÿ“Š Audience metrics and dynamics

Since its creation on ะฝะตะฒั–ะดะพะผะพ, the project has demonstrated rapid growth, gathering an audience of 13 355 subscribers.

According to the latest data from 27 June, 2026, the channel demonstrates stable activity. Although there has been a change in the number of participants by 213 over the last 30 days and by -17 over the last 24 hours, overall reach remains high.

  • Verification status: Not verified
  • Engagement rate (ER): The average audience engagement rate is 27.63%. Within the first 24 hours after publication, content typically collects 9.86% reactions from the total number of subscribers.
  • Post reach: On average, each post receives 3 695 views. Within the first day, a publication typically gains 1 318 views.
  • Reactions and interaction: The audience actively supports content: the average number of reactions per post is 36.
  • Thematic interests: Content is focused on key topics such as ู…ูŽุงุฏูŽู‘ุฉ, ุทูŽุงู„ูุจ, ุงูุณุชูุจููŠูŽุงู†, ุณูŽู„ูŽุงู…, ุฑูุณูŽุงู„ูŽุฉ.

๐Ÿ“ Description and content policy

The author describes the resource as a platform for expressing subjective opinions:
โ€œุจุณู… ุงู„ู„ู‡ ุงู„ุฑุญู…ู† ุงู„ุฑุญูŠู… ุงู„ู„ู‡ู… ุตู„ ุนู„ู‰ ู…ุญู…ุฏ ูˆุขู„ ู…ุญู…ุฏ ู…ุญุชูˆู‰ ุงู„ู‚ู†ุงุฉ: ุดุฑูˆุญุงุช ุตูŠุฏู„ุฉ ุนุถูˆูŠุฉ ู…ุฑุญู„ุฉ ุซุงู†ูŠุฉ ูƒูˆุฑุณ ุซุงู†ูŠ ูุงุฑู…ุง ู…ุฑุญู„ุฉ ุซุงู„ุซุฉ ูƒูˆุฑุณ ุซุงู†ูŠ ูุงุฑู…ุง ู…ุฑุญู„ุฉ ุฑุงุจุนุฉ ูƒูˆุฑุณ ุงูˆู„ ูุงุฑู…ุง ู…ุฑุญู„ุฉ ุฑุงุจุนุฉ ูƒูˆุฑุณ ุซุงู†ูŠ ุนู„ุงุฌูŠุงุช ู…ุฑุญู„ุฉ ุฎุงู…ุณุฉ ู„ู„ุชูˆุงุตู„: @AronX2botโ€

Thanks to the high frequency of updates (latest data received on 28 June, 2026), the channel maintains relevance and a high level of publication reach. Analytics show that the audience actively interacts with content, making it an important point of influence in the Medicine category.

13 355
Subscribers
-1724 hours
+3037 days
+21330 days
Posts Archive
A 44-year-old woman has been taking fluoxetine 20mg daily for six weeks for Major Depressive Disorder. She reports only minimal improvement in her mood and continues to experience significant fatigue and difficulty concentrating, what would be the MOST appropriate next step in her treatment? A) Changing the dose of fluoxetine. B) Switch to a different antidepressant, such as venlafaxine XR. C) Add bupropion SR to her existing fluoxetine regimen. D) Begin psychotherapy in addition to her medication. E) All of the above are valid therapeutic options 2025 ุฏูˆุฑ 1 ุณุคุงู„ ู…ู…ุชุงุฒ ูˆุงู„ู„ู‡ ูˆู„ูˆ ุงูƒูˆ ุฎู„ู„ ุจูˆุงุญุฏ ู…ู† ุงู„ุงุฎุชูŠุงุฑุงุช ุจุณ ุนุงุฏูŠ ูŠู…ุดูŠ ุญุงู„ ุญุฌูŠุฉ ุนุฏู‡ุง MDD ุงู„ุทุจูŠุจ ู…ู†ุทูŠู‡ุง Fluxetine ู…ุฏุฉ 6 ุงุณุงุจูŠุน ูˆุฑู‡ ู‡ุงู„ูุชุฑุฉ ุงู„ุญุฌูŠุฉ ุชู…ุงู… ุชุญุณู† ู…ุฒุงุฌู‡ุง ุจุณ ุจู‚ุช ุนุฏู‡ุง ุงู„ physical symptom ู…ุณุชู…ุฑุฉ ูŠุนู†ูŠ ุงุณุชุฌุงุจุชู‡ุง ุฌุฒุฆูŠุฉ ุดู†ูˆ ุงู„ุญู„ ุงู„ู…ู†ุงุณุจ ุงู„ูŠ ู…ู…ูƒู† ูŠุณูˆูŠู‡ ุงู„ุฏูƒุชูˆุฑ

R.K is 48 years old man diagnosed to have major depression on antidepressant. The physician checks blood pressure for this patient on cach visit. What do you expect the type of antidepressant used by this patient? A) SSRI B) MAO inhibitor C) TCA D) SNRI E) Serotonin and a2-adrenergic antagonists 2025 ุฏูˆุฑ 1 ุฑุญูŠู… ุงุจู† ุญุฌูŠ ูƒุฑูŠู… ุนู†ุฏู‡ ุงูƒุชุฆุงุจ ูˆุงู„ุทุจูŠุจ ู…ู†ุทูŠู‡ ุนู„ุงุฌ ุจุณ ุดู†ูˆ ูƒู„ู…ุง ูŠุฑุงุฌุน ุงู„ุทุจูŠุจ ุŒุงู„ุทุจูŠุจ ูŠฺ†ูŠูƒ ุถุบุทู‡ ุชุชูˆู‚ุนูˆู† ูŠุง ู…ุฌู…ูˆุนุฉ ู…ู†ุทูŠู‡ุง ุงู„ุทุจูŠุจ ุงู„ู‡ ูˆู„ูŠุด ุฏุงุฆู…ุง ูŠฺ†ูŠูƒ ุงู„ุถุบุทุŸ #MDD

#ุดุฎุงุจูŠุท

ุตูˆุฑ ู…ู…ูƒู† ุชุญุชุงุฌูˆู†ู‡ุง
+5
ุตูˆุฑ ู…ู…ูƒู† ุชุญุชุงุฌูˆู†ู‡ุง

ุงู‡ู†ุฆูƒู… ุจุนูŠุฏ ุงู„ูุทุฑ ุงู„ู…ุจุงุฑูƒ ุงุนุงุฏู‡ ุงู„ู„ู‡ ุนู„ูŠู†ุง ูˆุนู„ูŠูƒู… ุจุงู„ูŠู…ู† ูˆุงู„ุจุฑูƒุงุช ุงุณุฃู„ ุงู† ูŠูˆูู‚ูƒู… ุฌู…ูŠุนุง ููŠ ุงู„ุฃูŠุงู… ุงู„ู‚ุงุฏู…ุฉ ูˆูƒู„ ุนุงู… ูˆุฃู†ุชู… ุจุฃู„ู ุฎ
ุงู‡ู†ุฆูƒู… ุจุนูŠุฏ ุงู„ูุทุฑ ุงู„ู…ุจุงุฑูƒ ุงุนุงุฏู‡ ุงู„ู„ู‡ ุนู„ูŠู†ุง ูˆุนู„ูŠูƒู… ุจุงู„ูŠู…ู† ูˆุงู„ุจุฑูƒุงุช ุงุณุฃู„ ุงู† ูŠูˆูู‚ูƒู… ุฌู…ูŠุนุง ููŠ ุงู„ุฃูŠุงู… ุงู„ู‚ุงุฏู…ุฉ ูˆูƒู„ ุนุงู… ูˆุฃู†ุชู… ุจุฃู„ู ุฎูŠุฑโ™ฅ๏ธ

ุงู„ุณู„ุงู… ุนู„ูŠูƒู… ุดุจุงุจ ุทู„ุจุชูˆุง ู…ู†ูŠ ุนุงู„ุงู‚ู„ ุงูˆุถุญ ุงู„ุดุบู„ุงุช ุงู„ูŠ ูุงู‡ู…ู‡ุง ู…ู† ุงู„ุงุฏูุงู†ุณ ู…ุซู„ ุงู„ ir ูˆู…ุง ุญุจูŠุช ุงุฎู„ูŠ ุงู„ุดุฑุญ ู‡ู†ุง ุจุงู„ู‚ู†ุงุฉ ู„ุงู† ู‡ุงูŠ ุฎุงุตุฉ ุจู…ุงุฏุฉ ูƒุงู…ู„ุฉ ุนู„ุงุฌูŠุงุช ูˆู‡ูŠ ุงู„ุงุณุงุณ ูู‡ุงูŠ ุงู„ู‚ู†ุงุฉ ู„ุจุนุถ ู…ูˆุงุถูŠุน ุงู„ุงุฏูุงู†ุณ ูˆุงุชู…ู†ู‰ ุชููŠุฏูƒู… ุงู„ู…ู„ุงุญุธุงุช ุงู„ูŠ ุงุฏุฒู‡ุง ูˆู„ูˆ ุจุดูƒู„ ุจุณูŠุท https://t.me/advaronx2

ุดุจุงุจ ุจุงู„ู†ุณุจุฉ ู„ู„ุงุฏูุงู†ุณ ู…ู† ุฌู†ุช ุฎุงู…ุณุฉ ุฌู†ุช ู‚ูˆูŠ ุจู…ูˆุถูˆุน ุงู„ู€ ir ูƒู„ุด ูˆุทุจุนุง ู‡ุฐุง ู†ุชูŠุฌุฉ ู„ุดูŠ ุณูˆูŠุชู‡ ุทุจุนุง ู‡ุณู‡ ู…ุง ุงุชุฐูƒุฑ ุดูŠ ู…ู†ู‡ุง๐Ÿ˜ ุงู„ู…ู‡ู… ุจูˆู‚ุชู‡ุง ุจุนุฏ ู…ุง ูู‡ู…ุช ุงู„ุงุณุงุณูŠุงุช ูˆูŠ ุฏูƒุชูˆุฑ ุฑุงูุฏ ุฑุญุช ู†ุฒู„ุช ู…ู„ูุงุช ุจูŠู‡ุง ุฌุงุฑุชุงุช ู‡ูˆุงูŠ ูˆุถู„ูŠุช ุงุญู„ ู„ุญุฏ ู…ุง ุตุฑุช ู…ุชุฃูƒุฏ ุงู†ู‡ ู„ูˆ ูŠุฌูŠ ุงู„ู ุฌุงุฑุช ูˆุจุฃูŠ ุตูŠุบุฉ ุจุงู„ุงู…ุชุญุงู† ุฑุญ ุงุฌุงูˆุจ ุจุดูƒู„ ุตุญูŠุญ ุงู„ูŠ ุงุฑูŠุฏ ุงูƒูˆู„ู‡ ุงู†ู‡ ุญุชู‰ ุชุณูŠุทุฑูˆู† ุนู„ู‰ ู‡ุฐุง ุงู„ู…ูˆุถูˆุน ุฎุตูˆุตุง ู…ูˆุถูˆุน ุงู„ุฌุงุฑุชุงุช ู ุฏุงุฆู…ุง ุทู„ุนูˆุง ุฌุงุฑุชุงุช ู…ู† ูƒูˆูƒู„ ูˆุญู„ูˆู‡ู† ูƒุซุฑุฉ ุงู„ุชู…ุฑูŠู† ุฑุญ ุชุฎู„ูŠ ู‡ุงู„ู…ูˆุถูˆุน ุงุณู‡ู„ ุดูŠ ุจุงู„ุงุฏูุงู†ุณ ู…ุซู„ ู…ุง ุฌู†ุช ุงุดูˆูู‡ ูู‡ุงูŠ ุงู„ู…ู„ูุงุช ุงู„ูŠ ุฑุญ ุงู†ุฒู„ู‡ุง ุงู†ุง ุงุนุชู…ุฏุช ูˆุชู…ุฑู†ุช ุนู„ูŠู‡ุง ุจูˆู‚ุชู‡ุง ุงู† ุดุงุก ุงู„ู„ู‡ ุชููŠุฏูƒู… ุงู„ุงูˆู„ ุจูŠู‡ ุงู„ุชุฑุฏุฏุงุช ูˆุจุนุถ ุงู„ุงุณุงุณูŠุงุช ูˆุฌุงุฑุชุงุช ูˆุงู„ุจู‚ูŠุฉ ุจูŠู‡ู† ุฌุงุฑุชุงุช ุชุฏุฑุจูˆู† ุนู„ูŠู‡ู† ู…ุซู„ ุงู„ุงุณุฆู„ุฉ ุจุงู„ุชุนู„ูŠู‚ุงุช ๐Ÿ‘‡

ุงุฎูˆุงู† ุงู„ู…ุฑุญู„ุฉ ุงู„ุฑุงุจุนุฉ ุจุงู„ู†ุณุจุฉ ู„ุชุฃุดูŠุฑุงุช ุงู„ู…ู„ุงุฒู… ุชู„ูƒูˆู‡ู† ุจ ู‡ุฐุง ุงู„ูˆุณู… #ุชุฃุดูŠุฑุงุช ูˆูƒู„ุดูŠ ุชุญุชุงุฌูˆู† ุจ ุงู„ูุงุฑู…ุง ู…ุซุจุช ุงู„ูƒู… ุจู‡ุงูŠ ุงู„ุฑุณุงู„ุฉ ูˆุงู„ู…ู†ู‡ุฌ ู†ูุณู‡ ูกู ู ูช ูˆู‡ุฐุง ู„ู„ุชุฐูƒูŠุฑ ุฎุงู ุงุญุฏ ู†ุงุณูŠ๐Ÿ‘‡ https://t.me/Aronstudy/4065

Alzheimer disease is a progressive illness. Which Neurotransmitters involved in pathophysiology of Alzheimer disease? A- Acetylcholine B- Serotonin C-Glutamate D- Monoamine oxidase type B E- All are involvedโœ… 2022 ุฏูˆุฑ 1 ู‡ูˆ ุตุญ ู‡ุฐู†ูŠ ุงูƒุซุฑ ุดูŠ ุงู„ ach ูˆ Glutamate ุจุณ ูƒู„ ู‡ุฐู‡ ุงู„ Neurotransmitter ู…ู…ูƒู† ุชุณุงู‡ู… ููŠ ุญุฏูˆุซ ุงู„ุฒู‡ุงูŠู…ุฑ ุงู„ุฏุฑุงุณุงุช ู…ุณุชู…ุฑุฉ ูˆู…ู…ูƒู† ู…ุณุชู‚ุจู„ุง ู†ุดูˆู ุนู„ุงุฌุงุช ุซุงู†ูŠุฉ ุงู‚ูˆู‰ ู…ู† ุงู„ู…ุชูˆูุฑุฉ ุญุงู„ูŠุง ู„ู‡ุฐุง ุงู„ู…ุฑุถ #alzheimer

Mr. Ali, 71, with hypertension, presented with memory loss, financial management difficulties, and disorientation. His reduced social activities and mood swings indicated a cognitive decline. An MMSE score of 22 suggested mild Alzheimer's disease, confirmed by MRI. The following treatments can be used as monotherapy, EXCEPT: a- Donepezil b-Memantineโœ… c-Galantamine d- Rivastigmine e- Aducanumab #alzheimer

Ahmcd is a 65 years old man with severe Alzheimer disease. The suitable cholinesterase inhibitor is a- Rivastigmine b- Galantamine e- Aspirin ๐Ÿ˜’ d-Donepezil โœ… e- Lorazepam ุงู„ูˆุญูŠุฏ ู…ู† ุงุฏูˆูŠุฉ ุงู„ cholinestrase inhibitor ุงู„ูŠ ู…ู…ูƒู† ุงุณุชุฎุฏู…ู‡ ุจุญุงู„ุฉ ุงู„ severe #alzheimer

MRI baseline and ater treatcnt should be reconmended with : a- Rivastigmine b- Donepezil c- Aducanumab โœ… d- Galantamine e- Memuntine 2024 ุฏูˆุฑ 1 ุทุจุนุง ุชุญุณูˆู†ู‡ ุณุคุงู„ ู…ุง ูˆุงุถุญ ุงูˆ ุจูŠู‡ ู†ู‚ุต ุงู„ูˆุญูŠุฏ ู…ู† ุงุฏูˆูŠุฉ ุงู„ุฒู‡ุงูŠู…ุฑ ุงู„ูŠ ู†ุณูˆูŠ ูˆูŠุงู‡ MRI ู‡ูˆ Aducanumab ุจุณุจุจ ุงู„ุขุฑูŠุง ARIA ู…ุซู„ ู…ุง ูƒุชู„ูƒู… ู…ู…ูƒู† ูŠุณุจุจ ู†ุฒูŠู ุตุบูŠุฑ ููŠ ุงู„ุฏู…ุงุบ ุงูˆ edema ูˆุญุงู„ุฉ superficial siderosis ุงู„ูŠ ุงุฑุชูุงุน ู…ุงุฏุฉ ุงู„ hemosiderin ููŠ ุงู„ุงู… ุงู„ุญู†ูˆู† ุงูˆ ุงู„ุฌุงููŠุฉ #alzheimer

A 72-year-old male patient presents to the clinic with his daughter, a known case bf Alzheimer disease. On examination, the patient scores 18 on the Folstein Mini Mental State Examination (MMSE). The patient has a medical history for bradycardia and peptic ulcer. Which of the following is the most appropriate nitial pharmacologic treatment for this patient? 2025 ุฏูˆุฑ 1 A) Memantine monotherapy โœ… B) Aducanumab C) Donepezil D) Vitamin E supplementation E) Gabapentin #alzheimer

Which of the following antidepressants is NOT recommended for managing depression in Alzheimer's Disease? A) Sertraline B) Amitriptyline โœ… C) Citalopram D) Escitalopram E) Fluoxetine 2025 ุฏูˆุฑ 1 ุทุจุนุง ู…ุง ู…ุฐูƒูˆุฑ ู…ุซุงู„ ุนู„ูŠู‡ู† ุจุงู„ู…ู„ุฒู…ุฉ ุจุณ ุงู†ุชู… ุฑุญ ุชุงุฎุฐูˆู†ู‡ ุจู…ุญุงุถุฑุฉ ุงู„ depression ูˆู‡ู…ูŠู†ู‡ ุชุนุฑููˆู†ู‡ ุงูƒูŠุฏ ุงู†ุง ุจุงู„ุดุฑุญ ุฐูƒุฑุช ุงู„ูƒู… ู…ุซุงู„ูŠู†
ุงู„ู…ู‡ู… ุงู„ Tricyclic Antidepressant ู…ู…ู†ูˆุนุฉ ู„ู…ุฑูŠุถ ุงู„ุฒู‡ุงูŠู…ุฑ ู„ูŠุด ู„ุงู† ุนุฏู‡ู… anticholinergic effects ูˆู†ูุณ ุงู„ููƒุฑุฉ ู‡ู… ู‡ุงูŠ ุงู„ุงุฏูˆูŠุฉ ุชู‚ู„ู„ ู…ุณุชูˆู‰ ุงู„ ach ูˆุจุงู„ุชุงู„ูŠ ุชูุงู‚ู… ุญุงู„ุฉ ุงู„ู…ุฑูŠุถ
#alzheimer

What is the risk of abruptly stopping Cholinesterase inhibitors in Alzheimer's patients? A) Worsening cognitive function โœ… B) Increased seizures C) Gastrointestinal complications D) short memory loss E) No significant consequences 2025 ุฏูˆุฑ 1 ุฐูƒุฑุช ุงู„ูƒู… ุจุงู„ู…ุญุงุถุฑุฉ ุงู†ู‡ ู…ุง ูŠุตูŠุฑ ุงู„ู…ุฑูŠุถ ูŠุชุฑูƒ ู‡ุฐู‡ ุงู„ุงุฏูˆูŠุฉ ุจุตูˆุฑุฉ ู…ูุงุฌุฆุฉุŒ ู„ูŠุดุŸ
ู‡ูˆ ุงุตู„ุง ู…ุฑูŠุถ ุงู„ุฒู‡ุงูŠู…ุฑ ุตุงูŠุฑ ุนู†ุฏู‡ Loss of cholinergic neuron ูˆู…ุณุชูˆู‰ ุงู„ ach ูŠูƒูˆู† ู…ู†ุฎูุถ
๏ปฟ ู‡ุงูŠ ุงู„ุงุฏูˆูŠุฉ ุฑุญ ุชุนู…ู„ ุนู„ู‰ ุฒูŠุงุฏุฉ ู…ุณุชูˆู‰ ุงู„ Ach ู…ู† ุฎู„ุงู„ ุชุซุจูŠุท ุนู…ู„ cholinestrase enzyme
๐Ÿ”น ู ุงุฐุง ุชุฑูƒู‡ุง ุจุดูƒู„ ู…ุจุงุดุฑุŒ ุฑุญ ูŠุตูŠุฑ Sudden decline in Ach level ุงู†ุฎูุงุถ ุญุงุฏ ูˆุณุฑูŠุน ุจู…ุณุชูˆู‰ ุงู„ Ach ูˆุจุงู„ุชุงู„ูŠ ุชุชูุงู‚ู… ุนู†ุฏู‡ ุงู„ cognitive symptoms
#alzheimer